Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase EARLY_PHASE1 1

Status

Completed 47Terminated 4Not yet recruiting 2Unknown 1Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Conditions

Advanced Malignancies 2

Interventions

Cyclophosphamide 22fludarabine 17Specimen Handling 13Nivolumab 10pembrolizumab 9Magnetic Resonance Spectroscopy 9Radiotherapy 6Cisplatin 6fludarabine phosphate 5Interleukin-2 5Injections 5Doxorubicin 5tislelizumab 4daratumumab 4Paclitaxel 4Ipilimumab 4Immune Checkpoint Inhibitors 4Drug Therapy 4Dexamethasone 4Carboplatin 4Biopsy 4venetoclax 3trastuzumab deruxtecan 3toripalimab 3ruxolitinib 3X-Rays 3Vincristine 3Rituximab 3Radiosurgery 3Prednisone 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Not yet recruiting × Midazolam × Clear all
NCT07426757 2026-04-07

An Open-Label Study to Evaluate PF-07994525 in Participants With Advanced Cancers

Pfizer

Phase 1 Not yet recruiting
120 enrolled

Advanced Malignancies

NCT07340190 2026-04-02

A Drug-drug Interaction Study to Evaluate the Effects of Pelabresib on the Pharmacokinetics of Repaglinide, Midazolam, and Combined Oral Contraceptive in Patients With Advanced Malignancies

Novartis

Phase 1 Not yet recruiting
24 enrolled

Advanced Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡